Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. News
ImmunoPrecise Antibodies Ltd. Quantitative Score
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
ImmunoPrecise Antibodies Ltd. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
ImmunoPrecise Antibodies Ltd. Financials
Table Compare
Compare IPA metrics with: | |||
|---|---|---|---|
Earnings & Growth | IPA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | IPA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | IPA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | IPA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
ImmunoPrecise Antibodies Ltd. Income
ImmunoPrecise Antibodies Ltd. Balance Sheet
ImmunoPrecise Antibodies Ltd. Cash Flow
ImmunoPrecise Antibodies Ltd. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
ImmunoPrecise Antibodies Ltd. Executives
| Name | Role |
|---|---|
| Dr. Jennifer Lynne Bath Ph.D. | Chief Executive Officer, President & Non-Independent Director |
| Dr. Ilse Roodink | Chief Scientific Officer & Interim General Manager of IPA Europe, Oss |
| Ms. Kari Graber | Vice President of Commercial Services |
| Mr. Joseph Scheffler | Interim Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Jennifer Lynne Bath Ph.D. | Chief Executive Officer, President & Non-Independent Director | 720.25K | ||
| Dr. Ilse Roodink | Chief Scientific Officer & Interim General Manager of IPA Europe, Oss | 198.4K | ||
| Ms. Kari Graber | Vice President of Commercial Services | Female | 196.01K | |
| Mr. Joseph Scheffler | Interim Chief Financial Officer | Male | -- |
ImmunoPrecise Antibodies Ltd. Insider Trades
| Date | 12 Dec |
| Name | Aisling Capital II LP |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 10000 |
| Date | 12 Dec |
| Name | Aisling Capital II LP |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 1 |
| Date | 12 Dec |
| Name | Aisling Capital II LP |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 1 |
| Date | 12 Dec |
| Name | Aisling Capital II LP |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 10412 |
| Date | 12 Dec |
| Name | Aisling Capital II LP |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 861826 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 12 Dec | Aisling Capital II LP | 10 percent owner | Disposed | J-Other | 10000 |
| 12 Dec | Aisling Capital II LP | 10 percent owner | Disposed | J-Other | 1 |
| 12 Dec | Aisling Capital II LP | 10 percent owner | Acquired | J-Other | 1 |
| 12 Dec | Aisling Capital II LP | 10 percent owner | Acquired | J-Other | 10412 |
| 12 Dec | Aisling Capital II LP | 10 percent owner | Acquired | J-Other | 861826 |